RENB Stock Overview
A pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Renovaro Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.50 |
| 52 Week High | US$5.25 |
| 52 Week Low | US$0.40 |
| Beta | 0.54 |
| 11 Month Change | -22.81% |
| 3 Month Change | -26.85% |
| 1 Year Change | -83.42% |
| 33 Year Change | -95.44% |
| 5 Year Change | -91.60% |
| Change since IPO | -92.69% |
Recent News & Updates
Recent updates
Enochian stock climbs on US patent for oncology platform
Oct 17Enochian BioSciences discovers two sets of altered animal data in two of its studies
Jul 01Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?
Jun 28
Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Feb 20Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Oct 30Enochian Biosciences: A Follow Through For An HIV Cure
Jun 26Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment
Jun 14Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?
Feb 14Shareholder Returns
| RENB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.2% | -3.7% | 0.3% |
| 1Y | -83.4% | 15.2% | 31.1% |
Return vs Industry: RENB underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: RENB underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| RENB volatility | |
|---|---|
| RENB Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RENB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RENB's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 25 | David Weinstein | renovarobio.com |
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
Renovaro Inc. Fundamentals Summary
| RENB fundamental statistics | |
|---|---|
| Market cap | US$79.96m |
| Earnings (TTM) | -US$115.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs RENB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RENB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$115.69m |
| Earnings | -US$115.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.8% |
How did RENB perform over the long term?
See historical performance and comparison